Breadcrumb

Phase 2 Trial Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Doctor speaking with patient

Doctor speaking with patient. Image credit: Canva 

A clinical trial led by Christopher J. Melani, M.D., Associate Research Physician in the Lymphoid Malignancies Branch is testing the effectiveness of a combination targeted therapy known as ViPOR for patients with relapsed and/or refractory aggressive B-cell lymphoma. 

The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center. 

For more information, please contact the NCI Cancer Information Service at 1-888-624-1937 or nciinfo@mail.nih.gov  

Clinicaltrials.gov identifier: NCT06649812 

Trial ID: IRB002389 

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox. 

Posted on Thu, 09/04/2025